covid-19 epidemic is coming to an end
is the big consumption track hot again?
In early trading on the 21st, near the Spring Festival, tourist hotels rebounded strongly, and covid-19 detection and biomedicine fell sharply.
In the leading sector, airports, tourism, hotels, Baijiu and other gainers are among the top gainers.
Among the leading losers, in vitro diagnosis, covid-19 pneumonia detection and the previous popular leading gainers led the decline.
Among them, covid-19 pneumonia detection sector depth adjustment, Andon Health Co.Ltd(002432) , Zhejiang Orient Gene Biotech Co.Ltd(688298) limit. Changchun High And New Technology Industries (Group) Inc(000661) the limit fell for three consecutive days, and vaccine stocks continued to be under pressure.
The military industry sector broke lower, Avic Heavy Machinery Co.Ltd(600765) fell to the limit, Avic Shenyang Aircraft Company Limited(600760) , Avic Aviation High-Technology Co.Ltd(600862) hit the limit. Petrochina Company Limited(601857) fell more than 4%, and the oil and gas sector continued to be depressed.
Industry insiders believe that the epidemic in China has been initially controlled, and the epidemic in Xi’an has entered the final stage. Today, good news came from Henan. On January 20, the diagnosis in Henan fell to single digits for the first time since January 5. In addition, European and American countries have relaxed epidemic prevention and control policies. In addition, covid-19 oral medicine for pneumonia has frequently spread good news recently, and covid-19 testing sector and medical material export sector have been adjusted.
major shareholder pledge to be closed?
260 million big orders fled “northeast yaomao”
Affected by the centralized purchase documents, “northeast yaomao” has fallen by the limit for two consecutive times. In early trading on the 21st, the capital sentiment continued to deteriorate, and the limit fell directly during the call auction. So far, Changchun High And New Technology Industries (Group) Inc(000661) has fallen by the limit for three consecutive times.
As of the noon closing, Changchun High And New Technology Industries (Group) Inc(000661) was pressed on the limit by 140000 hand sales orders (about 260 million funds), and the total market value was only 74.6 billion yuan, which was nearly half of the total market value of 140 billion yuan at the peak.
It is understood that on the 20th, investors asked whether nearly 30 million shares of the Pledged Shares of major shareholders reached the closing line on January 20 will be closed?
Changchun High And New Technology Industries (Group) Inc(000661) said on the interactive platform that the pledge of relevant shares of major shareholders is the pledge guarantee provided for loans from relevant banks, which is not completely consistent with the setting of the closing line of pledge type repurchase transaction. The company will remind shareholders to pay full attention to the fluctuation of stock price and avoid relevant risks.
Changchun High And New Technology Industries (Group) Inc(000661) can’t hold
executives have increased their holdings of at the limit price
The leadership of Changchun High And New Technology Industries (Group) Inc(000661) can’t hold up after a continuous slump.
Just announced at noon, on January 21, 2022, the company received a notice from Chairman Ma Ji, director and general manager Jiang Yuntao, director and Executive Deputy General Manager Ye Peng, director and deputy general manager Wang Zhigang, chairman of the board of supervisors Xie Bing, supervisor Zhao Shuping, deputy general manager Li Xiufeng, deputy general manager and financial director Zhu Xinggong, and Board Secretary Zhang Deshen, On the same day, the above personnel increased their holdings of 84700 shares of the company through centralized bidding.
pharmaceutical sector “cried”
20 cm daily limit of mosadon covid-19 oral drug
In early trading on the 21st, Changchun High And New Technology Industries (Group) Inc(000661) made the funds crazy to flee the pharmaceutical sector. Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) , Nanjing Hicin Pharmaceutical Co.Ltd(300584) , North China Pharmaceutical Company.Ltd(600812) , Sailong Pharmaceutical Group Co.Ltd(002898) , Chimin Health Management Co.Ltd(603222) , Changzhou Qianhong Biopharma Co.Ltd(002550) also fell by the intraday limit.
Among them, bull stocks Nanjing Hicin Pharmaceutical Co.Ltd(300584) 20% fell by the limit during the year.
However, both Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) and Brightgene Bio-Medical Technology Co.Ltd(688166) opened the limit. As of the close, 100 billion big white horse Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) failed to hold the trading limit, up only 7.58%.
Small cap stocks Brightgene Bio-Medical Technology Co.Ltd(688166) rose by the word limit.
On the news side, on January 20 local time, the medicines patent pool (MPP) announced that it had signed agreements with several enterprises including Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) to produce and supply high-quality and affordable molnupiravir generic drugs for anti-covid-19 virus in mursadong for 105 low – and middle-income countries or regions around the world, To promote the affordability and accessibility of oral anti-covid-19 drugs in low – and middle-income countries and help local epidemic prevention and control.
Molnupiravir is an oral ribonucleoside analogue under development, which can inhibit the replication of sars-cov-2 (the pathogenic factor of covid-19 virus). It was jointly developed by MSD and Ridgeback. It is the first approved oral anti-covid-19 virus drug in the world. It was first approved by the British drug and Health Products Administration (MHRA) in November 2021, In December 2021, it obtained the emergency use authorization of the U.S. Food and Drug Administration (FDA) and the emergency special approval of the Ministry of health, labor and welfare of Japan.
Since MSD and Ridgeback jointly developed molnupiravir, the global supply of the drug has been a key priority for the two companies. It is worth noting that recently, at the time of the surge of Omicron infection cases in the United States, the news of serious supply shortage of covid-19 oral drug was also reported.
According to the securities times, in addition to Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , four Chinese pharmaceutical enterprises have been shortlisted in the agreement list. Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Brightgene Bio-Medical Technology Co.Ltd(688166) , Shijiazhuang Longze pharmaceutical and Shanghai deseno are licensed to produce molnupiravir API and finished product at the same time, while Langhua pharmaceutical under viabio is licensed to produce molnupiravir API. Two of the above five companies are listed companies, namely Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) and Brightgene Bio-Medical Technology Co.Ltd(688166) .
fourth quarter net profit decreased
70 billion media leaders approach the limit
In early trading on the 21st, affected by the decline in net profit in the fourth quarter, the once “media tycoon” Mango Excellent Media Co.Ltd(300413) plummeted by nearly 9%.
2021 is a “miserable” year for long video company. The industry has been rectified for many times, including but not limited to network Qinglang action, rice circle management, talent show management, and artist Yide events. Chinese variety shows and TV dramas have been greatly affected.
Despite many industry rectifications, Mango Excellent Media Co.Ltd(300413) remained profitable, mango TV members also exceeded the 50 million mark and maintained a high growth rate of 40%.
However, compared with 2020, the net profit of Mango Excellent Media Co.Ltd(300413) in the fourth quarter of 2021 will decline year-on-year due to the suspension of the program “happy camp” of Hunan Satellite TV and the change of content.
On the 20th, Mango Excellent Media Co.Ltd(300413) disclosed the performance forecast for 2021. It is expected that the annual net profit attributable to the parent company will be RMB 2.04 billion ~ 2.14 billion, with a year-on-year increase of 2.92% – 7.96%; Deduct non net profit of RMB 2 billion to RMB 2.1 billion, with a year-on-year increase of 8.33% – 13.75%.
Mango Excellent Media Co.Ltd(300413) Q3 net profit is 529 million yuan. Based on this calculation, Q4 net profit is expected to be RMB 60 million to RMB 160 million, with a significant decrease month on month.
Mango Excellent Media Co.Ltd(300413) the relevant person in charge said that the net profit in 2021q4 fell month on month. On the one hand, it was affected by the epidemic, and some programs were delayed. On the other hand, marketing and other expenses have increased. Xiaomang e-commerce is in the cultivation period. The fourth quarter is the traditional peak season of e-commerce. The company increased its investment in the fourth quarter.
